Mayo Clinic | Strategic Alliance Partners

August 17, 2022

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

August 16, 2022

At the start of his career, Weijing Sun, MD, FACP, was motivated to explore potential new treatments for gastrointestinal malignancies, and is now an internationally known GI cancer expert.

July 13, 2022

The clinical learning environment for medical trainees is the foundation of medical training programs.

June 30, 2022

The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma

June 23, 2022

Sikander Ailawadhi, MD, discusses early efficacy observed with iopofosine I-131, the rationale of investigating the agent in the CLOVER WaM trial in patients with Waldenström macroglobulinemia, and how the radiotherapeutic could affect the treatment paradigm.

June 06, 2022

Treatment with tafasitamab plus lenalidomide demonstrated trends toward improved overall survival vs systemic regimens across key subgroups of patients with high-risk relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant, according to findings from an observational, retrospective analysis of the cohort RE-MIND2 study.

June 06, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

June 03, 2022

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

May 20, 2022

Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.

May 12, 2022

Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.

May 10, 2022

Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.

May 10, 2022

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

April 26, 2022

Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.

March 31, 2022

Shaji K. Kumar, MD, discusses key takeaways from each presentation on chronic lymphocytic leukemia, myelofibrosis, relapsed/refractory diffuse large B-cell lymphoma, CAR T-cell therapy, and multiple myeloma.

March 15, 2022

Stephen M. Ansell, MD, PhD, discusses the evolving treatment landscape in diffuse large B-cell lymphoma.

March 04, 2022

Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.

January 12, 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the promise of non–VEGF inhibitor platforms in hepatocellular carcinoma.

December 22, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

December 17, 2021

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

December 11, 2021

The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.